Abstract
Aim:
FTY720, a new immunomodulatory drug with low cytotoxicity, is currently used to treat multiple sclerosis. In this study, we investigated the effects of FTY720 on inflammatory cell infiltration in albumin overload-induced nephropathy of rats.
Methods:
Male Wistar rats were subjected to right-side nephrectomy and divided into 3 groups. One week after the surgery, albumin overload (AO) group was treated with BSA (5 g·kg−1·d−1, ip) for 9 weeks; AO+FTY720 group was given BSA (5 g·kg−1·d−1, ip) plus FTY720 (0.5 g·kg−1·d−1, ip) for 9 weeks; and control group received daily ip injection of equivalent volume of saline. All rats were killed 9 weeks after nephrectomy.
Results:
AO rats exhibited gradually increased urinary protein excretion accompanied by elevated urinary N-acetyl-β-O-glucosaminidase activity, and both reached their peak values at week 7. Furthermore, AO significantly increased lymphocytes and monocytes in circulation and the inflammatory cells recruited to tubulointerstitium, and the expression of inflammatory cytokines MCP-1, TNF-α and IL-6, as well as sphingosine 1-phosphate (S1P) receptors S1pr1 and S1pr3, and S1P-synthesizing enzyme sphingosine kinase 1 (Sphk1) in the kidney. Concomitant administration of FTY720 significantly attenuated all the AO-induced pathological changes.
Conclusion:
FTY720 alleviates tubulointerstitium inflammation in an AO rat model of nephropathy via down-regulation of the Sphk1 pathway.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305.
Abbate M, Zoja C, Remuzzi G . How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974–84.
Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Graler M, Heusch G, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011; 108: 314–23.
Lee SB, Kalluri R . Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010: S22–6.
Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883–97.
Chun J, Brinkmann V . A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 2011; 12: 213–28.
Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006; 107: 1454–8.
Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 2010; 207: 1475–83.
Kveberg L, Bryceson Y, Inngjerdingen M, Rolstad B, Maghazachi AA . Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur J Immunol 2002; 32: 1856–64.
Ni HF, Chen JF, Zhang MH, Pan MM, Zhang JD, Liu H, et al. FTY720 attenuates tubulointerstitial inflammation and fibrosis in subtotally nephrectomized rats. Ren Fail 2013; 35: 996–1004.
Jo SK, Bajwa A, Ye H, Vergis AL, Awad AS, Kharel Y, et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int 2009; 75: 167–75.
Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int 2011; 79: 1090–8.
Gadola L, Noboa O, Marquez MN, Rodriguez MJ, Nin N, Boggia J, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004; 65: 1224–30.
Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 2011; 286: 18633–40.
Gorriz JL, Martinez-Castelao A . Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando) 2012; 26: 3–13.
Ding LH, Liu D, Xu M, Liu H, Wu M, Tang RN, et al. Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats. Acta Pharmacol Sin 2014; 35: 1293–301.
Muller GA, Markovic-Lipkovski J, Frank J, Rodemann HP . The role of interstitial cells in the progression of renal diseases. J Am Soc Nephrol 1992; 2: S198–205.
Cyster JG . Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127–59.
Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, Blaho V, et al. Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest 2011; 121: 2290–300.
Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346–9.
Lewis ND, Haxhinasto SA, Anderson SM, Stefanopoulos DE, Fogal SE, Adusumalli P, et al. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. J Immunol 2013; 190: 3533–40.
Rivera J, Proia RL, Olivera A . The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008; 8: 753–63.
Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J 2009; 23: 143–52.
Snider AJ, Orr Gandy KA, Obeid LM . Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 2010; 92: 707–15.
Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008; 53: 997–1012.
Awad AS, Ye H, Huang L, Li L, Foss FW Jr, Macdonald TL, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006; 290: F1516–24.
Martini S, Kramer S, Loof T, Wang-Rosenke Y, Daig U, Budde K, et al. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. Am J Physiol Renal Physiol 2007; 292: F1761–70.
Sui M, Zhou J, Xie R, Liu X, Mu S, Jia X, et al. The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis. Mol Biol Rep 2012; 39: 389–97.
Pedregosa JF, Haidar AA, Hirata AE, Franco M, Gomes GN, Bueno V . TLR2 and TLR4 expression after kidney ischemia and reperfusion injury in mice treated with FTY720. Int Immunopharmacol 2011; 11: 1311–8.
Acknowledgements
This study was supported by grants from the Key Project of the National Natural Science Foundation of China (No 81130010), and Project of Jiangsu Clinical Medical Science (No BL2014080) to Prof Bi-cheng LIU.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xu, M., Liu, D., Ding, Lh. et al. FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway. Acta Pharmacol Sin 35, 1537–1545 (2014). https://doi.org/10.1038/aps.2014.100
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2014.100
Keywords
This article is cited by
-
Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1
Acta Pharmacologica Sinica (2015)
